Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir
Authors:
- 1 May 2017
- journal article
- research article
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 75 (3) , 176-184
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Development and Validation of the Chiral HPLC Method for Daclatasvir in Gradient Elution Mode on Amylose-Based Immobilized Chiral Stationary PhaseChromatographia, 2016
- Development and validation of sensitive and rapid UPLC–MS/MS method for quantitative determination of daclatasvir in human plasma: Application to a bioequivalence studyJournal of Pharmaceutical and Biomedical Analysis, 2016
- Daclatasvir: A Review in Chronic Hepatitis CDrugs, 2016
- Daclatasvir in hepatitis C virus infection: a guide to its use in the EUDrugs & Therapy Perspectives, 2016
- New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvirExpert Review of Clinical Pharmacology, 2015
- Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2015
- Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5ACurrent Medicinal Chemistry, 2014
- A sensitive and accurate liquid chromatography–tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urineJournal of Chromatography A, 2012